Evidence map›Paper›PMID 31035702›Full record

ArticleBiomolecules2019

Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses.

Consolación Garcia-Contreras, Marta Vazquez-Gomez, José Luis Pesantez-Pacheco, Laura Torres-Rovira, Ana Heras-Molina, Teresa Encinas, Susana Astiz, Antonio Gonzalez-Bulnes

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Consolación Garcia-ContrerasSGIT-INIA, 28040 Madrid, Spain. garcia.consolacion@inia.es.
Marta Vazquez-GomezFaculty of Veterinary Medicine, Universidad Complutense de Madrid (UCM), Ciudad Universitaria s/n, 28040 Madrid, Spain. mvgomez@ucm.es.ORCID 0000-0002-8916-2086
José Luis Pesantez-PachecoSGIT-INIA, 28040 Madrid, Spain. jose.pesantez@ucuenca.edu.ec.ORCID 0000-0002-5669-6014
Laura Torres-RoviraSGIT-INIA, 28040 Madrid, Spain. torrerovi@gmail.com.
Ana Heras-MolinaSGIT-INIA, 28040 Madrid, Spain. delasheras.ana@inia.es.ORCID 0000-0001-7496-9680
Teresa EncinasFaculty of Veterinary Medicine, Universidad Complutense de Madrid (UCM), Ciudad Universitaria s/n, 28040 Madrid, Spain. tencinas@vet.ucm.es.
Susana AstizSGIT-INIA, 28040 Madrid, Spain. astiz.susana@inia.es.ORCID 0000-0002-9718-0903
Antonio Gonzalez-BulnesSGIT-INIA, 28040 Madrid, Spain. bulnes@inia.es.ORCID 0000-0002-0917-4475
Universidad Complutense de Madrid · ESUniversity of Cuenca · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin is an anti-hyperglycemic drug widely used for the treatment of insulin resistance and glucose intolerance and is currently considered for preventing large-for-gestational-age (LGA) offspring in pregnant women affected by obesity or diabetes. Our hypothesis was the opposite-metformin may be used for improving the development of offspring affected by intrauterine growth restriction (IUGR) and preventing the appearance of small-for-gestational-age (SGA) neonates in non-obese and non-diabetic but malnourished pregnancies. The current study, performed in a swine preclinical model of IUGR by undernutrition, showed that fetuses in the treated group showed no significant increases in body-weight, but showed a significantly higher weight of the brain, the total thoracic and abdominal viscera, the liver, the kidneys, the spleen, and the adrenal glands. Maternal metformin treatment was also related to significant increases in the fetal plasma concentration of parameters indicative of glycemic (glucose and fructosamine) and lipid profiles (triglycerides). Overall, these results suggest a protective effect of the treatment on the developmental competence of the fetuses. These findings may be of high value for human medicine in case of maternal malnutrition, since metformin is a cheap drug easily available, but also in case of placental deficiency, since metformin seems to improve placental development and function.

Indexed as

AnimalsBody SizeBody WeightFemaleFetal Growth RetardationFetusMetforminOrgan SizePregnancySwineMetforminintrauterine-growth-restrictionmetforminpregnancyswine-model

Identifiers

PMID31035702
PMCPMC6572102
OpenAlexW2941639607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.